Zydus ties up with Dutch firm for novel cancer drug
Zydus Lifesciences has partnered with Synthon BV in a deal to develop, license, supply, and commercialize a novel oncology drug in the US. The agreement aims to target a $1.5 billion market, with Synthon handling development and manufacturing and Zydus overseeing NDA submission and commercialization. The product, expected in 2026, will offer features for improved patient compliance.
Zydus Lifesciences has partnered with Synthon BV in a deal to develop, license, supply, and commercialize a novel oncology drug in the US. The agreement aims to target a $1.5 billion market, with Synthon handling development and manufacturing and Zydus overseeing NDA submission and commercialization. The product, expected in 2026, will offer features for improved patient compliance.
